Generic Zimulti Active Ingredient: Rimonabant

Out of stock

Rimofabant under the brand names Acomplia and Zimulti refers to a group of new agents called Cannabinoid-1 Receptor Blockers and is intended for treatment of adiposity (obesity).

It lays siege to those receptors that are responsible for glucose and lipid metabolic process. It is also purposed to make endocannabinoid system less active. The latter has lately been claimed as a leading physiological system in the process of weight and energy balance regulation including glucose and lipid metabolic process.

The medication was developed for the people of Type 2 diabetes and with exceeding fat rate in the blood who are overweight.

The drug has not been proved right as an anti-smoking medication by FDA but it succeeded with the approval in the weight regulation.

The possible adverse affects can be vomiting and sickness.

The medication was developed by Sanofi-Aventis company and got an favourable reception at European Union marketing, though it is so far not approved in the USA.